Pharmaceutical & Diagnostic Innovation

, Volume 3, Issue 8, pp 17–21 | Cite as

Corporate Activity — Mergers and Acquisitions

News & View

Impending mergers and acquisitions

Bausch & Lomb, a global eye health company headquartered in Rochester, NY, has entered into a definitive agreement to acquire a 55% controlling interest in Shandong Chia Tai Freda Pharmaceutical (CTF), the leading ophthalmic pharmaceutical company in China, from Sino Biopharmaceutical. The purchase price of $US200 million in cash represents the equivalent of 18.6 times the Chinese company’s 2004 net earnings. The acquisition will accelerate Bausch & Lomb’s expansion into the rapidly growing ophthalmic pharmaceuticals market in China. In addition, Bausch & Lomb has agreed in principle to a future acquisition of an additional 15% interest in CTF for $US54.5 million. CTF primarily develops, manufactures and markets medications used to treat ocular inflammation and infection, glaucoma and dry eye. Further information is available from

Bionutrics of Phoenix, AZ, has entered into an agreement to purchase Florida-based Kirk...

Copyright information

© Adis Data Information BV 2005

Personalised recommendations